Giant-Cell Arteritis Epidemiology

• Giant Cell Arteritis (GCA) is a heterogeneous vasculitis disorder that commonly presents with new-onset temporal headache, scalp tenderness, jaw claudication, visual disturbances (including transient or permanent vision loss), and constitutional symptoms such as fatigue, fever, and weight loss, while large-vessel involvement may additionally lead to limb claudication or aortic complications. 
• Polymyalgia Rheumatica (PMR) is a recognized risk factor for GCA, with approximately 15% PMR patients developing GCA and about half of GCA patients exhibiting PMR symptoms.
• GCA is the most common primary systemic vasculitis in adults aged >50 years, with an age-adjusted incidence ranging approximately from 10–30 cases per 100,000 population (≥50 years) in Northern Europe and North America, while lower rates are reported in Southern Europe and Asia, indicating strong geographic variability.
• The disease shows a clear age and sex predilection, occurring almost exclusively in older adults (peak 70–80 years) and is 2–3 times more common in females than males, as consistently demonstrated in large epidemiological cohorts.
• Visual complications remain a major epidemiological burden, with historical data showing that untreated GCA leads to irreversible vision loss in patients, although early diagnosis and prompt corticosteroid initiation have significantly reduced this risk in contemporary clinical practice.

Giant Cell Arteritis (GCA) Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of GCA: ~XX
• 2036 Diagnosed Prevalent Cases of GCA: ~XX
• GCA Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Giant Cell Arteritis Epidemiology Forecast 2036’ report delivers an in-depth understanding of the GCA, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Giant Cell Arteritis (GCA) Understanding and Diagnosis Algorithm

GC Giant Cell Arteritis (GCA) Overview

GCA is an immune-mediated large-vessel vasculitis affecting individuals over 50 years, driven by abnormal immune activation likely triggered by genetic and environmental factors. The disease causes inflammation of arterial walls, leading to vessel narrowing and reduced blood flow. GCA diagnosis is based on clinical evaluation supported by elevated inflammatory markers, including ESR and CRP. Confirmation is achieved through temporal artery biopsy, which remains the diagnostic gold standard. Imaging techniques such as vascular ultrasound (halo sign), MRI, and PET are increasingly used to detect cranial and large-vessel involvement, enabling earlier and less invasive diagnosis.

Further details are provided in the report.

Giant Cell Arteritis (GCA) Diagnosis

Diagnosis of GCA is based on clinical assessment, supported by elevated inflammatory markers such as ESR and CRP. Temporal artery biopsy remains the gold standard for confirmation, demonstrating granulomatous inflammation and multinucleated giant cells. Increasingly, non-invasive imaging is used to support early diagnosis, including vascular ultrasound (halo sign), MRI, and PET, which help detect large-vessel involvement. Diagnosis is often challenging due to nonspecific symptoms, leading to delayed recognition. Therefore, there is strong emphasis on early imaging-based diagnosis and prompt initiation of corticosteroid therapy to prevent irreversible vision loss.

Further details are provided in the report.

Giant Cell Arteritis (GCA) Epidemiology

Key Findings from GCA Epidemiological Analysis and Forecast 

• GCA is the most common primary systemic vasculitis in adults over 50 years, with incidence increasing sharply with advancing age. Epidemiological studies consistently show that the disease is strongly age-dependent, with the highest burden observed in individuals in their seventh and eighth decades of life (around 70–80 years), while cases below 50 years are rare.
• GCA affects approximately 100 people per million worldwide and around 20 per 100,000 individuals in the United States. 
• GCA typically develops after the age of 50, is most common among individuals aged 70–79 years, is rare in children, occurs about twice as frequently in females as in males, and is more prevalent among people of Northern European ancestry.
• The incidence of GCA demonstrates significant geographic variation, with higher rates reported in Northern European populations, typically ranging from approximately 10–30 per 100,000 individuals aged 50 years and above, whereas lower incidence is observed in Southern Europe and Asian populations. This variation is well documented in population-based registries and is thought to reflect both genetic susceptibility and environmental influences.
• GCA shows a clear female predominance, with women being affected approximately two to three times more frequently than men, as consistently reported across multiple cohort studies and registry data analyses.
• Overall, despite being a relatively rare disease in absolute terms, GCA represents a clinically significant burden in the elderly population, with increasing recognition driven by improved diagnostic imaging and heightened clinical awareness in rheumatology practice.                            

Scope of the Report

• The report covers a segment of a descriptive overview of hand eczema, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression. 

Report Insights

Giant Cell Arteritis (GCA) Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of hand eczema? What will be the growth opportunities across the 7MM concerning the patient population with hand eczema?
• What is the historical and forecasted hand eczema patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.